Story perspectives

Kura Oncology and Replimune Grant New Employee Stock Options

3/8/2025

29 3

Summary

Story summary

Kura Oncology granted stock options to six new employees on March 3, 2025, under its 2023 Inducement Option Plan.
Each option permits the purchase of 190,000 shares at an exercise price of $7.25, vesting over four years.
Replimune Group awarded inducement equity to 10 new employees, including options for 11,085 shares and 22,225 restricted stock units.
Replimune's options have a $12.29 exercise price and also vest over four years, in compliance with Nasdaq regulations.

1 of 1

Story summary

Kura Oncology granted stock options to six new employees on March 3, 2025, under its 2023 Inducement Option Plan.
Each option permits the purchase of 190,000 shares at an exercise price of $7.25, vesting over four years.
Replimune Group awarded inducement equity to 10 new employees, including options for 11,085 shares and 22,225 restricted stock units.
Replimune's options have a $12.29 exercise price and also vest over four years, in compliance with Nasdaq regulations.